• evo真人视讯

    Swiss Guests Visit Shenzhen Cell Valley——Discussing the Deepening of Science and Technology Integration with Industry on the Occasion of the 75th Anniversary of the Establishment of Diplomatic Relatio

    Date:03-06  Hits:  Belong to:Corporate News

     


    Recently, Mr.Yunlong Song, Member of the Swiss Federal Ministry of Culture, Ms.Li Ying, Chairperson of the China-Switzerland 75th Anniversary Summit Forum, Mr.Hans Strub, Advisor of the Forum, and Mr.Chen Sihan, Sponsor of the Forum,visited Shenzhen Cell Valley to conduct in-depth exchanges and collaborative discussions.Professor Shi Yuanyuan, Chairman of our company, Mr.Fu Yuchen, Assistant to the Chairman, and Ms.Sun Rui,Director of the Marketing Department, extended a warm welcome. Both sides engaged in discussions on topics such as technological innovation in cell therapy and international industrial cooperation.



    Accompanied by Chairman's Assistant Fu Yuchen, the visiting guests first toured the Shenzhen Cell Valley Smart Exhibition Hall, where they gained a systematic understanding of the company's full industrial chain layout in the field of cell and gene therapy. As the only CRO/CDMO service provider in China with clinical-grade GMP industrial production capacity for retroviral vectors (RVV), Shenzhen Cell Valley has established a production line exceeding 10,000 square meters that meets international GMP standards for viral vectors and cell products. The single-batch production capacity of RVV exceeds 1,000 human units, and the CAR-T cell transduction efficiency reaches over 70%.



    At the symposium, Professor Shi Yuanyuan, Chairman of the Board, extended a warm welcome to all distinguished guests. He emphasized that Shenzhen Cell Valley has always adhered to the mission of 'Cells benefiting all beings, genes creating the future.' The company has not only established the Cell Therapy Translational Research Institute in collaboration with Shenzhen Hospital of Southern Medical University but also engaged in deep cooperation with institutions such as the National Engineering Research Center for Key Common Technologies in the Cell Industry, building a comprehensive service platform covering the entire lifecycle from vector design to clinical application. Looking ahead, Shenzhen Cell Valley will leverage the opportunity of the 75th Anniversary Summit Cooperation Forum of China-Switzerland Diplomatic Relations to foster exchanges and collaborations with the Swiss medical and pharmaceutical sectors.


    Mr.Hans Strub stated that as a strategic high ground in the field of biomedicine, cell therapy urgently requires cross-border resource integration and technological iteration. Mr.Yunlong Song, Member of the Federal Ministry of Culture of Switzerland, also expressed his willingness to leverage this visit as an opportunity to build a bridge for Sino-Swiss collaboration in the cell therapy industry, facilitating the global dissemination of innovative achievements in life sciences between the two countries.


    Professor Shi Yuanyuan stated that Shenzhen Cell Valley is committed to promoting international scientific and cultural exchanges and cooperation, hoping to further enhance the internationalization level of cell therapy technology through collaboration with the Swiss medical community. This exchange is an important action for Shenzhen Cell Valley to implement its internationalization strategy. In the future, the company will continue to adopt an open and innovative cooperative attitude, working with global partners to explore new frontiers in cell technology, contributing China's wisdom and Shenzhen's strength to the cause of human health.


    About Us
    Scan to follow our latest newsScan to follow our latest news
    Contact Us
    400-800-1266

    Working hours: Monday to Friday, 9:00-18:00

    Contact:Ms. Lai

    Email:laijiaqi@rodael.com

    Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

    Bottom Navigation
    Shenzhen Cell Valley Biopharmaceutical Co., Ltd.​​ is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.
     Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software